{"transactions":[{"id":825308,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-30T12:46:52.000Z","date":"2026-03-27","kind":"purchase","planned":false,"acquired":true,"shares":7500,"price":8.57,"value":64275.0,"ownership":{"direct":true},"balance_after":12886,"source":{"system":"sec-edgar","filing":"0001706176-26-000004","document":"wk-form4_1774874809.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000170617626000004/wk-form4_1774874809.xml","form_type":"4"}},{"id":946965,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-06T21:21:45.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). \"RSU Grant Date\" shall mean January 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the RSUs subject to the award shall vest on the one (1) year anniversary of the RSU Grant Date, and one eighth (1/8th) of the RSUs subject to the award shall vest every six (6) months thereafter on the same day of the month as the RSU Grant Date (and if there is no corresponding day, on the last day of the month). \"RSU Grant Date\" shall mean January 2, 2026."}],"balance_after":14000,"derivative":{"underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001706176-26-000002","document":"wk-form4_1767734500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000170617626000002/wk-form4_1767734500.xml","form_type":"4"}},{"id":946964,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:21:45.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":84200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean January 2, 2026."}],"balance_after":84200,"derivative":{"exercise_price":16,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":84200},"source":{"system":"sec-edgar","filing":"0001706176-26-000002","document":"wk-form4_1767734500.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000170617626000002/wk-form4_1767734500.xml","form_type":"4"}},{"id":1004954,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-08T00:42:43.000Z","date":"2025-11-07","kind":"purchase","planned":false,"acquired":true,"shares":2178,"price":22.7561,"value":49562.7858,"ownership":{"direct":true},"balance_after":5386,"source":{"system":"sec-edgar","filing":"0001815776-25-000072","document":"wk-form4_1762562560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000072/wk-form4_1762562560.xml","form_type":"4"}},{"id":1004953,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-08T00:42:43.000Z","date":"2025-11-07","kind":"purchase","planned":false,"acquired":true,"shares":20,"price":22.71,"value":454.2,"ownership":{"direct":true},"balance_after":3208,"source":{"system":"sec-edgar","filing":"0001815776-25-000072","document":"wk-form4_1762562560.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000072/wk-form4_1762562560.xml","form_type":"4"}},{"id":1304368,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-13T22:22:51.000Z","date":"2025-01-09","kind":"grant","planned":false,"acquired":true,"shares":70444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean January 9, 2025."}],"balance_after":70444,"derivative":{"exercise_price":26.34,"expiration_date":"2035-01-08","underlying":"Common Stock","underlying_shares":70444},"source":{"system":"sec-edgar","filing":"0001815776-25-000005","document":"wk-form4_1736806964.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000005/wk-form4_1736806964.xml","form_type":"4"}},{"id":1516077,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-05-15T20:13:06.000Z","date":"2024-05-14","kind":"purchase","planned":false,"acquired":true,"shares":3188,"price":15.68,"value":49987.84,"ownership":{"direct":true},"balance_after":3188,"source":{"system":"sec-edgar","filing":"0001815776-24-000046","document":"wk-form4_1715803974.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000046/wk-form4_1715803974.xml","form_type":"4"}},{"id":1561964,"issuer":{"id":6475,"kind":"organization","name":"LENZ Therapeutics, Inc."},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-26T00:36:10.000Z","date":"2024-03-21","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, twenty five percent (25%) of the shares subject to the option shall vest on the one (1) year anniversary of the Vesting Commencement Date, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). \"Vesting Commencement Date\" shall mean March 21, 2024."}],"balance_after":200000,"derivative":{"exercise_price":15.05,"expiration_date":"2034-03-20","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001815776-24-000023","document":"wk-form4_1711413359.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815776/000181577624000023/wk-form4_1711413359.xml","form_type":"4"}},{"id":1579310,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-13T20:29:45.000Z","date":"2024-03-12","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total shares subject to the Option will vest each month on the same day of the month as the Vesting Commencement Date (as defined below), and if there is no corresponding day, the last day of the month, subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Equity Incentive Plan through each such date. The Vesting Commencement Date is January 1, 2024."}],"balance_after":200000,"derivative":{"exercise_price":0.985,"expiration_date":"2034-03-12","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-24-004825","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919124004825/doc4.xml","form_type":"4"}},{"id":1616791,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Restricted Stock Units","published_at":"2024-02-27T19:54:13.000Z","date":"2024-02-25","kind":"exercise","planned":false,"acquired":false,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."}],"balance_after":34444,"derivative":{"underlying":"Common Stock","underlying_shares":6889},"source":{"system":"sec-edgar","filing":"0001209191-24-004037","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919124004037/doc4.xml","form_type":"4"}},{"id":1616790,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2024-02-27T19:54:13.000Z","date":"2024-02-27","kind":"sale","planned":false,"acquired":false,"shares":3405,"price":0.7322,"value":2493.141,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 3,405 shares sold in the price range of $0.7316 to $0.7411 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":102306,"source":{"system":"sec-edgar","filing":"0001209191-24-004037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919124004037/doc4.xml","form_type":"4"}},{"id":1616789,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2024-02-27T19:54:13.000Z","date":"2024-02-25","kind":"exercise","planned":false,"acquired":true,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":105711,"source":{"system":"sec-edgar","filing":"0001209191-24-004037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919124004037/doc4.xml","form_type":"4"}},{"id":1728868,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Restricted Stock Units","published_at":"2023-11-28T19:06:17.000Z","date":"2023-11-25","kind":"exercise","planned":false,"acquired":false,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."}],"balance_after":41333,"derivative":{"underlying":"Common Stock","underlying_shares":6889},"source":{"system":"sec-edgar","filing":"0001209191-23-056842","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123056842/doc4.xml","form_type":"4"}},{"id":1728867,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-11-28T19:06:17.000Z","date":"2023-11-28","kind":"sale","planned":false,"acquired":false,"shares":3720,"price":0.5,"value":1860.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."}],"balance_after":98822,"source":{"system":"sec-edgar","filing":"0001209191-23-056842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123056842/doc4.xml","form_type":"4"}},{"id":1728866,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-11-28T19:06:17.000Z","date":"2023-11-25","kind":"exercise","planned":false,"acquired":true,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":102542,"source":{"system":"sec-edgar","filing":"0001209191-23-056842","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123056842/doc4.xml","form_type":"4"}},{"id":1794468,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Restricted Stock Units","published_at":"2023-08-29T18:47:04.000Z","date":"2023-08-25","kind":"exercise","planned":false,"acquired":false,"shares":6888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25, and November 25 of each year."}],"balance_after":48222,"derivative":{"underlying":"Common Stock","underlying_shares":6888},"source":{"system":"sec-edgar","filing":"0001209191-23-047665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123047665/doc4.xml","form_type":"4"}},{"id":1794467,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-08-29T18:47:04.000Z","date":"2023-08-28","kind":"sale","planned":false,"acquired":false,"shares":3512,"price":1.45,"value":5092.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."}],"balance_after":95653,"source":{"system":"sec-edgar","filing":"0001209191-23-047665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123047665/doc4.xml","form_type":"4"}},{"id":1794466,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-08-29T18:47:04.000Z","date":"2023-08-25","kind":"exercise","planned":false,"acquired":true,"shares":6888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":99165,"source":{"system":"sec-edgar","filing":"0001209191-23-047665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123047665/doc4.xml","form_type":"4"}},{"id":1877006,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Restricted Stock Units","published_at":"2023-05-26T19:29:02.000Z","date":"2023-05-25","kind":"exercise","planned":false,"acquired":false,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":55110,"derivative":{"underlying":"Common Stock","underlying_shares":6889},"source":{"system":"sec-edgar","filing":"0001209191-23-032707","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123032707/doc4.xml","form_type":"4"}},{"id":1877005,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-05-26T19:29:02.000Z","date":"2023-05-25","kind":"sale","planned":false,"acquired":false,"shares":3635,"price":1.4196,"value":5160.246,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 3,635 shares sold in the price range of $1.41 to $1.42 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":92277,"source":{"system":"sec-edgar","filing":"0001209191-23-032707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123032707/doc4.xml","form_type":"4"}},{"id":1877004,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-05-26T19:29:02.000Z","date":"2023-05-25","kind":"exercise","planned":false,"acquired":true,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":95912,"source":{"system":"sec-edgar","filing":"0001209191-23-032707","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123032707/doc4.xml","form_type":"4"}},{"id":1948138,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-17T16:57:12.000Z","date":"2023-03-16","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total shares subject to the Option will vest each month on the same day of the month as the Vesting Commencement Date (as defined below), and if there is no corresponding day, the last day of the month, subject to the Reporting Person continuing to be a Service Provider in accordance with the Company's 2021 Equity Incentive Plan through each such date. The Vesting Commencement Date is January 1, 2023."}],"balance_after":200000,"derivative":{"exercise_price":1.65,"expiration_date":"2033-03-16","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-23-019728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123019728/doc4.xml","form_type":"4"}},{"id":1987939,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Restricted Stock Units","published_at":"2023-02-28T18:22:56.000Z","date":"2023-02-25","kind":"exercise","acquired":false,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":61999,"derivative":{"underlying":"Common Stock","underlying_shares":6889},"source":{"system":"sec-edgar","filing":"0001209191-23-013854","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123013854/doc4.xml","form_type":"4"}},{"id":1987938,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-02-28T18:22:56.000Z","date":"2023-02-27","kind":"sale","acquired":false,"shares":3599,"price":1.6812,"value":6050.6388,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 3,599 shares sold in the price range of $1.68 to $1.72 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":89023,"source":{"system":"sec-edgar","filing":"0001209191-23-013854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123013854/doc4.xml","form_type":"4"}},{"id":1987937,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2023-02-28T18:22:56.000Z","date":"2023-02-25","kind":"exercise","acquired":true,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":92622,"source":{"system":"sec-edgar","filing":"0001209191-23-013854","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919123013854/doc4.xml","form_type":"4"}},{"id":2102736,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Restricted Stock Units","published_at":"2022-11-29T17:33:13.000Z","date":"2022-11-25","kind":"exercise","acquired":false,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":68888,"derivative":{"underlying":"Common Stock","underlying_shares":6889},"source":{"system":"sec-edgar","filing":"0001209191-22-058981","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122058981/doc4.xml","form_type":"4"}},{"id":2102735,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2022-11-29T17:33:13.000Z","date":"2022-11-28","kind":"sale","acquired":false,"shares":3532,"price":2.7196,"value":9605.6272,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 3,532 shares sold in the price range of $2.70 to $2.72 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":85733,"source":{"system":"sec-edgar","filing":"0001209191-22-058981","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122058981/doc4.xml","form_type":"4"}},{"id":2102734,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2022-11-29T17:33:13.000Z","date":"2022-11-25","kind":"exercise","acquired":true,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":89265,"source":{"system":"sec-edgar","filing":"0001209191-22-058981","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122058981/doc4.xml","form_type":"4"}},{"id":2172158,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Restricted Stock Units","published_at":"2022-08-29T21:14:09.000Z","date":"2022-08-25","kind":"exercise","acquired":false,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":75777,"derivative":{"underlying":"Common Stock","underlying_shares":6889},"source":{"system":"sec-edgar","filing":"0001209191-22-047948","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122047948/doc4.xml","form_type":"4"}},{"id":2172157,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2022-08-29T21:14:09.000Z","date":"2022-08-26","kind":"sale","acquired":false,"shares":3655,"price":4.0162,"value":14679.211,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 3,655 shares sold in the price range of $4.01 to $4.13 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":82376,"source":{"system":"sec-edgar","filing":"0001209191-22-047948","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122047948/doc4.xml","form_type":"4"}},{"id":2172156,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2022-08-29T21:14:09.000Z","date":"2022-08-25","kind":"exercise","acquired":true,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":86031,"source":{"system":"sec-edgar","filing":"0001209191-22-047948","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122047948/doc4.xml","form_type":"4"}},{"id":2254052,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Restricted Stock Units","published_at":"2022-05-27T17:27:56.000Z","date":"2022-05-25","kind":"exercise","acquired":false,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":82666,"derivative":{"underlying":"Common Stock","underlying_shares":6889},"source":{"system":"sec-edgar","filing":"0001209191-22-032665","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122032665/doc4.xml","form_type":"4"}},{"id":2254051,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2022-05-27T17:27:56.000Z","date":"2022-05-26","kind":"sale","acquired":false,"shares":3596,"price":1.9011,"value":6836.3556,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 3,596 shares sold in the price range of $1.90 to $1.95 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":79142,"source":{"system":"sec-edgar","filing":"0001209191-22-032665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122032665/doc4.xml","form_type":"4"}},{"id":2254050,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2022-05-27T17:27:56.000Z","date":"2022-05-25","kind":"exercise","acquired":true,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":82738,"source":{"system":"sec-edgar","filing":"0001209191-22-032665","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122032665/doc4.xml","form_type":"4"}},{"id":2325132,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-18T17:35:44.000Z","date":"2022-03-17","kind":"grant","acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the shares subject to the option shall vest on the date one month following February 23, 2022 (the \"Vesting Commencement Date\"), and one forty-eighth (1/48th) of the total shares subject to the option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each such date."}],"balance_after":195000,"derivative":{"exercise_price":3.04,"expiration_date":"2032-03-17","underlying":"Common Stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001209191-22-020080","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122020080/doc4.xml","form_type":"4"}},{"id":2366396,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Restricted Stock Units","published_at":"2022-03-01T21:10:34.000Z","date":"2022-02-25","kind":"exercise","acquired":false,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":89555,"derivative":{"underlying":"Common Stock","underlying_shares":6889},"source":{"system":"sec-edgar","filing":"0001209191-22-014438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122014438/doc4.xml","form_type":"4"}},{"id":2366395,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2022-03-01T21:10:34.000Z","date":"2022-02-28","kind":"sale","acquired":false,"shares":3998,"price":2.7795,"value":11112.441,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 3,998 shares sold in the price range of $2.7101 to $2.84 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":75849,"source":{"system":"sec-edgar","filing":"0001209191-22-014438","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122014438/doc4.xml","form_type":"4"}},{"id":2366394,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2022-03-01T21:10:34.000Z","date":"2022-02-25","kind":"exercise","acquired":true,"shares":6889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":79847,"source":{"system":"sec-edgar","filing":"0001209191-22-014438","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919122014438/doc4.xml","form_type":"4"}},{"id":2493560,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Restricted Stock Units","published_at":"2021-11-29T19:48:53.000Z","date":"2021-11-25","kind":"exercise","acquired":false,"shares":13777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"One-eighth (1/8th ) of the RSU Award will vest on November 25, 2021 (the \"First Vesting Date\"), and one-sixteenth (1/16th ) of the RSU Award will vest each Quarterly Vesting Date (as defined below) after the First Vesting Date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Subsidiary, Inc. 2016 Equity Incentive Plan, the \"Plan\") through the applicable vesting date. For the purposes of the foregoing, \"Quarterly Vesting Date\" means February 25, May 25, August 25,and November 25 of each year."}],"balance_after":96444,"derivative":{"underlying":"Common Stock","underlying_shares":13777},"source":{"system":"sec-edgar","filing":"0001209191-21-067045","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121067045/doc4.xml","form_type":"4"}},{"id":2493559,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2021-11-29T19:48:53.000Z","date":"2021-11-29","kind":"sale","acquired":false,"shares":4325,"price":4.8191,"value":20842.6075,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average share price of an aggregate total of 4,325 shares sold in the price range of $4.62 to $5.34 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":72958,"source":{"system":"sec-edgar","filing":"0001209191-21-067045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121067045/doc4.xml","form_type":"4"}},{"id":2493558,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2021-11-29T19:48:53.000Z","date":"2021-11-26","kind":"sale","acquired":false,"shares":3254,"price":4.8006,"value":15621.1524,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the reporting person's award agreement to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average share price of an aggregate total of 3,254 shares sold in the price range of $4.7150 to $5.01 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":77283,"source":{"system":"sec-edgar","filing":"0001209191-21-067045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121067045/doc4.xml","form_type":"4"}},{"id":2493557,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2021-11-29T19:48:53.000Z","date":"2021-11-25","kind":"exercise","acquired":true,"shares":13777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of Viracta Therapeutics, Inc. Common Stock."}],"balance_after":80537,"source":{"system":"sec-edgar","filing":"0001209191-21-067045","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121067045/doc4.xml","form_type":"4"}},{"id":2556932,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-29T18:04:18.000Z","date":"2021-09-28","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the total shares subject to the Option will vest on the one (1)-year anniversary of July 30, 2019 (the \"Vesting Commencement Date\") and 1/48th of the total shares subject to the Option will vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, the last day of the month), subject to the reporting person continuing to be a Service Provider in accordance with Viracta Subsidiary, Inc.'s 2016 Equity Incentive Plan (the \"Plan\") through each such date."}],"balance_after":88817,"derivative":{"exercise_price":0.9,"expiration_date":"2029-07-30","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-058099","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121058099/doc4.xml","form_type":"4"}},{"id":2556931,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2021-09-29T18:04:18.000Z","date":"2021-09-28","kind":"exercise","acquired":true,"shares":10000,"price":0.9,"value":9000.0,"ownership":{"direct":true},"balance_after":66760,"source":{"system":"sec-edgar","filing":"0001209191-21-058099","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121058099/doc4.xml","form_type":"4"}},{"id":2689597,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-01T17:49:14.000Z","date":"2021-05-28","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent (25%) of the total shares subject to the Option will vest on the one (1)-year anniversary of July 30, 2019 (the \"Vesting Commencement Date\") and 1/48th of the total shares subject to the Option will vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, the last day of the month), subject to the reporting person continuing to be a Service Provider in accordance with Viracta Subsidiary, Inc.'s 2016 Equity Incentive Plan (the \"Plan\") through each such date."}],"balance_after":98817,"derivative":{"exercise_price":0.9,"expiration_date":"2029-07-30","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-21-036907","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121036907/doc4.xml","form_type":"4"}},{"id":2689596,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Common Stock","published_at":"2021-06-01T17:49:14.000Z","date":"2021-05-28","kind":"exercise","acquired":true,"shares":12000,"price":0.9,"value":10800.0,"ownership":{"direct":true},"balance_after":56760,"source":{"system":"sec-edgar","filing":"0001209191-21-036907","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121036907/doc4.xml","form_type":"4"}},{"id":2768365,"issuer":{"id":85616,"kind":"organization","name":"Viracta Therapeutics, Inc.","symbol":"VIRX"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-30T20:00:30.000Z","date":"2021-03-26","kind":"grant","acquired":true,"shares":78912,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One forty-eighth (1/48th) of the Shares subject to the Option shall vest on the one (1) month anniversary of March 26, 2021 (the \"Vesting Commencement Date\"), and one forty-eighth (1/48th) of the Shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the reporting person continuing to be a Service Provider (as defined in the Viracta Therapeutics, Inc. 2021 Equity Incentive Plan) through each such date."}],"balance_after":78912,"derivative":{"exercise_price":8.74,"expiration_date":"2031-03-26","underlying":"Common Stock","underlying_shares":78912},"source":{"system":"sec-edgar","filing":"0001209191-21-023636","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1061027/000120919121023636/doc4.xml","form_type":"4"}},{"id":3470445,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-07-02T17:41:20.000Z","date":"2019-07-01","kind":"sale","acquired":false,"shares":2669,"price":1.3115,"value":3500.3935,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 2/5/2019. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":77870,"source":{"system":"sec-edgar","filing":"0001209191-19-040500","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119040500/doc4.xml","form_type":"4"}},{"id":3523254,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-16T17:57:59.000Z","date":"2019-05-14","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 5, 2019, the reporting person was granted an option to purchase the number of shares of common stock set forth in Box 5.  The option vests only upon the achievement of a performance-based milestone.  The performance criteria were met, resulting in vesting of the option.  Upon achievement of the milestone, 50% of the options subject to the milestone immediately vest, with the remaining options vesting in 24 equal monthly installments following the vesting commencement date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The original Form 4, filed on May 16, 2019, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the number of shares reported in Boxes 7 and 9.  As a result of this administrative error, the number of shares beneficially owned by the reporting person following the reported transaction was incorrectly reported."}],"balance_after":8000,"derivative":{"exercise_price":0.95,"exercise_date":"2019-05-14","expiration_date":"2029-02-04","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001209191-19-030569","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119030569/doc4a.xml","form_type":"4/A","original_submission_date":"2019-05-16"}},{"id":3523253,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-16T17:21:46.000Z","date":"2019-05-14","kind":"grant","acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On February 5, 2019, the reporting person was granted an option to purchase the number of shares of common stock set forth in Box 5.  The option vests only upon the achievement of a performance-based milestone.  The performance criteria were met, resulting in vesting of the option.  Upon achievement of the milestone, 50% of the options subject to the milestone immediately vest, with the remaining options vesting in 24 equal monthly installments following the vesting commencement date."}],"balance_after":7500,"derivative":{"exercise_price":0.95,"exercise_date":"2019-05-14","expiration_date":"2029-02-04","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-19-030506","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119030506/doc4.xml","form_type":"4"}},{"id":3523252,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-05-16T17:21:46.000Z","date":"2019-05-15","kind":"sale","acquired":false,"shares":10000,"price":1.4089,"value":14089.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 5/14/2019.  These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person."}],"balance_after":80539,"source":{"system":"sec-edgar","filing":"0001209191-19-030506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119030506/doc4.xml","form_type":"4"}},{"id":3523251,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-05-16T17:21:46.000Z","date":"2019-05-14","kind":"grant","acquired":true,"shares":55414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On November 11, 2018, the reporting person was granted Restricted Stock Units in the Company's tender offer.  The RSUs vest only upon the achievement of a performance-based milestone.  The performance criteria were met, resulting in vesting of the RSUs.  Upon achievement of the milestone, 50% of the RSU subject to the milestone immediately vest, with the remaining RSUs vesting quarterly in the 24 months following the vesting commencement date."}],"balance_after":90539,"source":{"system":"sec-edgar","filing":"0001209191-19-030506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119030506/doc4.xml","form_type":"4"}},{"id":3563872,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-04-03T16:16:32.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":3253,"price":0.9814,"value":3192.4942,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares of common stock under an existing 10b5-1 Plan to cover tax withholding obligations incurred in connection with the vesting of the restricted stock unit award received by the Reporting Person on 2/5/2019."}],"balance_after":9372,"source":{"system":"sec-edgar","filing":"0001209191-19-023087","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119023087/doc4.xml","form_type":"4"}},{"id":3672068,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-06T16:50:42.000Z","date":"2019-02-05","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest ratably on a monthly basis over a 48 month period subject to the reporting person's continuous service to Regulus through each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":0.95,"expiration_date":"2029-02-04","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-19-007774","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119007774/doc4.xml","form_type":"4"}},{"id":3672067,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-06T16:50:42.000Z","date":"2019-02-05","kind":"grant","acquired":true,"shares":30000,"price":0.95,"value":28500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted Stock Units which vest ratably on a quarterly basis such that the grant is fully vested on December 31, 2019, subject to the reporting person's continuous service to Regulus through each such vesting date."}],"balance_after":34578,"source":{"system":"sec-edgar","filing":"0001209191-19-007774","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919119007774/doc4.xml","form_type":"4"}},{"id":3923611,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-21T16:37:06.000Z","date":"2018-05-17","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in forty-eight equal monthly installments, such that the option will be fully vested four years from the date of grant, subject to the Reporting Person's continuous service to us."}],"balance_after":250000,"derivative":{"exercise_price":0.71,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-18-031884","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919118031884/doc4.xml","form_type":"4"}},{"id":4105115,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-05T18:55:39.000Z","date":"2018-01-05","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in forty-eight equal monthly installments, such that the option will be fully vested four years from the date of grant, subject to the Reporting Person's continuous service to us."}],"balance_after":350000,"derivative":{"exercise_price":1.24,"expiration_date":"2028-01-04","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001209191-18-002554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919118002554/doc4.xml","form_type":"4"}},{"id":4251703,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-07-25T18:07:23.000Z","date":"2017-07-25","kind":"purchase","acquired":true,"shares":54945,"price":0.91,"value":49999.95,"ownership":{"direct":true},"balance_after":59415,"source":{"system":"sec-edgar","filing":"0001209191-17-046232","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919117046232/doc4.xml","form_type":"4"}},{"id":4322381,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":55330,"kind":"person","name":"Chevallard Daniel R.","position":1,"cik":"0001706176","reported_name":"Chevallard Daniel R.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-12T16:48:28.000Z","date":"2017-05-10","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares vest on May 10, 2018 and the remainder of the shares vest in equal installments on a monthly basis thereafter, such that the option is fully vested on May 10, 2021."}],"balance_after":100000,"derivative":{"exercise_price":1.65,"expiration_date":"2027-05-09","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-17-032011","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1505512/000120919117032011/doc4.xml","form_type":"4"}}]}